Project Grant R01AG092547
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$622K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the J. David Gladstone Institutes is focused on exploring the role of the NOX2 enzyme in mediating brain dysfunction associated with Alzheimer's disease (AD). The $842,175 award, spanning December 2024 to November 2029, aims to investigate how inhibiting NOX2 could mitigate AD-related pathologies such as amyloid-beta and tau protein accumulation, network hyperactivity, glucose...
The Project Grant award for "NEURODEGENERATIVE REPROGRAMING OF MICROGLIA IN ALZHEIMER'S DISEASE" was provided by the National Institute on Aging (CFDA 93.866 Aging Research) in the amount of $442,357.00. The grant, awarded to the Research Foundation of the City University of New York (RFCUNY), aims to elucidate the molecular mechanisms underlying a specific subset of stressed "dark" microglia and their neurodegenerative impact in Alzheimer's disease (AD) models. The...
This $2,119,771 Project Grant award from the National Institute on Aging (under CFDA 93.866 - Aging Research) will fund research at the University of Massachusetts Medical School (UMass Medical) to investigate the role of peripheral insulin resistance and inflammation in Alzheimer's disease (AD) pathogenesis. The project aims to define age-related changes in metabolism and inflammation in peripheral organs, particularly the liver, and examine how these processes impact AD-relevant...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This $125,896 Project Grant, awarded by the National Institute on Aging under the Aging Research program (CFDA 93.866), supports a research project led by The Washington University in St. Louis. The project aims to utilize state-of-the-art single-nuclei multi-omic functional genomic analyses of healthy and Alzheimer's disease (AD) human brain tissue, as well as transgenic AD mouse models, to perform deep molecular characterization of AD risk and resilience pathways across genetic, epigenomic,...
This federal Project Grant award, provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), aims to develop and apply advanced statistical methods to improve scientific inferences in Alzheimer's disease (AD) research. The key products and services to be delivered through this $455,274 award made to The Johns Hopkins University include: Developing efficient and statistically proper methods to better model, estimate, and predict the risk of AD incidence...
This $445,625 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to develop an innovative nanotechnology approach to interrupt amyloid-beta (Aβ)-scavenger receptor (SR) signaling and mitigate neuroinflammation in Alzheimer's disease (AD). The research aims to: (1) elucidate how SR-targeted nanoparticles can ameliorate Aβ-mediated glial cell dysfunction and inflammatory pathways; and (2) evaluate the long-term neuroprotective...
This federal Project Grant award for $500,000, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports the development of a novel, multi-target peptide drug called ALZ100 for the treatment of Alzheimer's disease (AD). The grantee, Alzarrok Bio LLC, is conducting in vivo studies in an AD mouse model to demonstrate ALZ100's ability to inhibit key disease drivers, including amyloid-beta oligomers, the RAGE and TLR4 receptors, and the S100A9 protein. The goal is to show...
This Project Grant award, issued by the National Institute on Aging under CFDA 93.866 - Aging Research, provides $636,000.00 in funding to the University of Pittsburgh to develop and evaluate novel NOX2 small molecule inhibitors as a potential therapeutic strategy for treating Alzheimer's disease (AD) and related dementias. The research aims to assess the ability of the inhibitors CPP11G and CPP11H to improve cerebrovascular blood flow, reduce amyloid-beta deposition, and mitigate microglial...
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) will support research to elucidate the mechanisms by which microgliopathy, a type of brain disease, causes early-onset dementia. The $427,625 award to The Washington University in St. Louis will fund a 2-year research project to investigate the role of the signaling pathways RUNX1/2 and STAT3 in driving gene expression changes that may alter microglial functions and lead to brain...